Embecta Corp.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Embecta Corp. (Nasdaq: EMBC) develops, manufactures and sells a range of injectable products primarily focused on diabetes care, including insulin pens, pen needles, syringes and safety devices such as InPen smart insulin pens and OneTouch Verio blood glucose meters; the company also offers digital applications for diabetes management and safety-engineered syringes for other therapeutic areas. Headquartered in Parsippany, New Jersey, Embecta was founded in 1924 as part of the original Becton Dickinson spin-off and became an independent entity in 2022 following its separation from BD. The company operates globally, with manufacturing facilities and sales in North America, Europe, Asia-Pacific and Latin America, targeting healthcare providers, pharmacies and patients managing chronic conditions. In recent developments, Embecta announced a strategic partnership with LifeScan in 2024 to integrate continuous glucose monitoring data with its InPen platform, enhancing digital diabetes solutions; the company also completed a $250 million debt refinancing in mid-2025 to strengthen its balance sheet amid market expansion efforts.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EMBC
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EMBC
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EMBC
Embecta: A Sharp Decline On Q2 Earnings, But There's Still No Opportunity
Embecta Rallies After UK Firm Deal Worth $200 Million
Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)
Upgrading Embecta Due To Reorganization And Growth Initiatives
Embecta: Strategic Reprioritization Holds Promise And Valuations Are Favorable
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
New Initiatives Expected To Make Embecta More Profitable
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
Why Embecta Stock Is Tanking Today
Embecta: Mammoth Effort Needed To Get Investors Over The Line, Reiterate Hold
UPDATE -- embecta to Participate in Investor Conferences
embecta to Participate in Investor Conferences
embecta to Report Fiscal Second Quarter 2023 Financial Results
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
Why Embecta Stock Popped by Nearly 13% Today
embecta to Participate in Upcoming Investor Conferences
embecta to Report Fiscal First Quarter 2023 Financial Results